Risk of Type 2 Diabetes, MASLD and Cardiovascular Disease in People Living With Polycystic Ovary Syndrome
The Journal of Clinical Endocrinology & Metabolism · 22.04.2025 · 110 (5) · 1235-1246
DOI: 10.1210/clinem/dgae481 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Clinical Endocrinology & Metabolism, online erschienen am 11.07.2024. Verfasst von Alex E Henney und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiovascular & Metabolic Medicine, University of Liverpool, Liverpool L69 7ZX, UK. Hauptthemen laut MEDLINE: Polycystic Ovary Syndrome, Diabetes Mellitus, Type 2, Cardiovascular Diseases, Fatty Liver. Die Arbeit wurde bisher 28-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Diabetes mellitus
Abstract (Originalsprache)
Background
Polycystic ovary syndrome (PCOS) is associated with adverse clinical outcomes that may differ according to PCOS phenotype.
Methods
Using UK Biobank data, we compared the incidence of type 2 diabetes (T2D), metabolic dysfunction associated steatotic liver disease, cardiovascular disease (CVD), hormone-dependent cancers, and dementia between PCOS participants and age- and body mass index-matched controls. We also compared multiorgan (liver, cardiac, and brain) magnetic resonance imaging (MRI) data and examined the impact of PCOS phenotype (hyperandrogenic and normoandrogenic) on these outcomes.
Results
We included 1008 women with PCOS (defined by diagnostic codes, self-reported diagnoses, or clinical/biochemical features of hyperandrogenism and a/oligoCmenorrhoea) and 5017 matched controls (5:1 ratio); median age, 61 years, body mass index, 28.4 kg/m². Adjusted Cox proportional hazard modeling demonstrated PCOS participants had greater incident T2D [hazard ratio (HR) 1.47; 95% confidence interval (CI), 1.11-1.95] and all-cause CVD (1.76; 1.35-2.30). No between-group differences existed for cancers or dementia. Liver MRI confirmed more PCOS participants had hepatic steatosis (proton density fat fraction >5.5%: 35.9 vs 23.9%; P = .02) and higher fibroinflammation (corrected T1 721.4 vs 701.5 ms; P = <.01) vs controls. No between-group difference existed for cardiac (biventricular/atrial structure and function) or brain (grey and white matter volumes) imaging. Normoandrogenic (but not hyperandrogenic) PCOS participants had greater incident all-cause CVD (1.82; 1.29-2.56) while hyperandrogenic (but not normoandrogenic) PCOS participants were more likely to have hepatic steatosis (8.96 vs 6.04 vs 5.23%; P = .03) with greater fibroinflammation (776.3 vs 707.7 vs 701.9 ms; P=<.01).
Conclusion
Cardiometabolic disease may be increased in PCOS patients with a disease phenotype-specific pattern.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Cardiovascular & Metabolic Medicine, University of Liverpool, Liverpool L69 7ZX, UK.
- Metabolism & Nutrition Research Group, Liverpool University Hospitals NHS Foundation Trust, Liverpool, Merseyside L9 7AL, UK.
- Liverpool Centre for Cardiovascular Sciences, University of Liverpool and Liverpool University Hospitals NHS Foundation Trust, Liverpool, Merseyside L69 7ZX, UK.
- Department of Clinical Neurosciences, University of Cambridge, Cambridge CB2 3PT, UK.
- Department of Public Health, Policy & Systems, University of Liverpool, Liverpool, Merseyside L69 7ZX, UK.
- Warwick Medical School, University of Warwick, Coventry CV4 7AL, UK.
ORCID-Profile: Alex E Henney
Zitieren
APA
Henney, A. E., Gillespiec, C. S., Lai, J. Y. M., Schofield, P., Riley, D. R., Caleyachetty, R., Barber, T. M., Miras, A. D., Dobbie, L. J., Hughes, D. M., Alam, U., Hydes, T. J., & Cuthbertson, D. J. (2025). Risk of Type 2 Diabetes, MASLD and Cardiovascular Disease in People Living With Polycystic Ovary Syndrome. The Journal of Clinical Endocrinology & Metabolism, 110(5), 1235-1246. https://doi.org/10.1210/clinem/dgae481
Vancouver
Henney AE, Gillespiec CS, Lai JYM, Schofield P, Riley DR, Caleyachetty R, et al. Risk of Type 2 Diabetes, MASLD and Cardiovascular Disease in People Living With Polycystic Ovary Syndrome. The Journal of Clinical Endocrinology & Metabolism. 2025;110(5):1235-1246. doi:10.1210/clinem/dgae481
BibTeX
@article{Henney2025,
author = {Henney, Alex E and Gillespiec, Conor S and Lai, Jonathan Y M and Schofield, Pieta and Riley, David R and Caleyachetty, Rishi and Barber, Thomas M and Miras, Alexander D and Dobbie, Laurence J and Hughes, David M and Alam, Uazman and Hydes, Theresa J and Cuthbertson, Daniel J},
title = {Risk of Type 2 Diabetes, MASLD and Cardiovascular Disease in People Living With Polycystic Ovary Syndrome},
journal = {The Journal of Clinical Endocrinology & Metabolism},
year = {2025},
volume = {110},
number = {5},
pages = {1235--1246},
doi = {10.1210/clinem/dgae481}
}
EUVIMED